Shares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) gapped down prior to trading on Monday following a dissappointing earnings announcement. The stock had previously closed at $10.38, but opened at $9.90. UroGen Pharma shares last traded at $11.19, with a volume of 402,553 shares traded.
The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09).
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday. Scotiabank began coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective for the company. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of UroGen Pharma in a research note on Monday, April 28th. Finally, The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $32.86.
Get Our Latest Stock Analysis on URGN
Institutional Investors Weigh In On UroGen Pharma
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC increased its stake in UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after purchasing an additional 48,040 shares during the last quarter. Tidal Investments LLC raised its stake in UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock worth $477,000 after acquiring an additional 6,030 shares in the last quarter. JPMorgan Chase & Co. lifted its position in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after acquiring an additional 49,318 shares during the last quarter. SG Americas Securities LLC boosted its stake in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock valued at $216,000 after acquiring an additional 6,207 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of UroGen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after purchasing an additional 1,402 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
UroGen Pharma Trading Up 8.2%
The stock has a market capitalization of $518.01 million, a price-to-earnings ratio of -3.56 and a beta of 0.66. The business has a 50-day moving average of $10.64 and a 200-day moving average of $10.97. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
